LIVIVO - Das Suchportal für Lebenswissenschaften

switch to English language
Erweiterte Suche

Suchergebnis

Treffer 1 - 10 von insgesamt 142

Suchoptionen

  1. Artikel: [Ⅲ.Estrogen Receptor and MicroRNA].

    Toyama, Tatsuya / Wanifuchi-Endo, Yumi

    Gan to kagaku ryoho. Cancer & chemotherapy

    2019  Band 46, Heft 12, Seite(n) 1844–1847

    Mesh-Begriff(e) Breast Neoplasms ; Cell Line, Tumor ; Estrogens ; Female ; Gene Expression Regulation, Neoplastic ; Humans ; MicroRNAs ; Receptors, Estrogen
    Chemische Substanzen Estrogens ; MicroRNAs ; Receptors, Estrogen
    Sprache Japanisch
    Erscheinungsdatum 2019-12-06
    Erscheinungsland Japan
    Dokumenttyp Journal Article
    ZDB-ID 604842-0
    ISSN 0385-0684
    ISSN 0385-0684
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Zs.B 2573: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  2. Artikel: [MicroRNA-210 in breast cancer].

    Toyama, Tatsuya

    Nihon rinsho. Japanese journal of clinical medicine

    2012  Band 70 Suppl 7, Seite(n) 170–173

    Mesh-Begriff(e) Breast Neoplasms/chemistry ; Cell Hypoxia ; Female ; Humans ; MicroRNAs/analysis ; MicroRNAs/genetics ; Prognosis
    Chemische Substanzen MIRN210 microRNA, human ; MicroRNAs
    Sprache Japanisch
    Erscheinungsdatum 2012-09
    Erscheinungsland Japan
    Dokumenttyp Journal Article
    ZDB-ID 390903-7
    ISSN 0047-1852
    ISSN 0047-1852
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Zs.A 429: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  3. Artikel ; Online: Ruptured breast implant removal because of patient anxiety in the absence of breast implant-associated anaplastic large cell lymphoma.

    Takahashi, Hitomi / Sato, Hideyoshi / Tsunekawa, Yukiyo / Fujioka, Urara / Wanifuchi-Endo, Yumi / Toyama, Tatsuya / Toriyama, Kazuhiro

    Nagoya journal of medical science

    2023  Band 85, Heft 4, Seite(n) 852–856

    Abstract: Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) has been regarded as a long-term problem after silicone breast implantations. We report a case in which BIA-ALCL and breast cancer were not detected preoperatively, with subsequent ... ...

    Abstract Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) has been regarded as a long-term problem after silicone breast implantations. We report a case in which BIA-ALCL and breast cancer were not detected preoperatively, with subsequent removal of a ruptured breast implant. A 52-year-old woman had silicone breast implants on both sides for breast augmentation 15 years ago. Right axillary lymphadenopathy and intracapsular ruptures were noted by magnetic resonance imaging. Right axillary lymph node biopsy was performed at our department of breast surgery. Flow cytometry for BIA-ALCL was also performed using the exudate around the implant. The results were negative for breast cancer and BIA-ALCL. However, taking into consideration exacerbation of breast implant rupture and the patient's anxiety about BIA-ALCL, ruptured bilateral implants were removed by total capsulectomy. The postoperative course was uneventful 1 year after the operation, and her anxiety was dispelled despite her breast deformity. Appropriate explantation and periodic examination may be required to prevent excessive anxiety.
    Mesh-Begriff(e) Humans ; Female ; Middle Aged ; Breast Implants/adverse effects ; Breast Implantation/adverse effects ; Breast Implantation/methods ; Lymphoma, Large-Cell, Anaplastic/etiology ; Lymphoma, Large-Cell, Anaplastic/surgery ; Mammaplasty/adverse effects ; Breast Neoplasms/surgery ; Breast Neoplasms/pathology ; Anxiety/etiology ; Silicones
    Chemische Substanzen Silicones
    Sprache Englisch
    Erscheinungsdatum 2023-12-18
    Erscheinungsland Japan
    Dokumenttyp Case Reports
    ZDB-ID 193148-9
    ISSN 2186-3326 ; 0027-7622
    ISSN (online) 2186-3326
    ISSN 0027-7622
    DOI 10.18999/nagjms.85.4.852
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Ua VI Zs.181: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  4. Artikel ; Online: Three-compartment spectral diffusion analysis for breast cancer magnetic resonance imaging.

    Ogawa, Masaki / Kan, Hirohito / Urano, Misugi / Kawai, Tatsuya / Nakajima, Haruna / Murai, Kazuma / Miyaji, Hirotaka / Toyama, Tatsuya / Hiwatashi, Akio

    Magnetic resonance imaging

    2023  Band 103, Seite(n) 179–184

    Abstract: Rationale and objectives: To examine the diagnostic performance of a three-compartment diffusion model with the fixed cut-off diffusion coefficient (D) using magnetic resonance spectral diffusion analysis for differentiating between invasive ductal ... ...

    Abstract Rationale and objectives: To examine the diagnostic performance of a three-compartment diffusion model with the fixed cut-off diffusion coefficient (D) using magnetic resonance spectral diffusion analysis for differentiating between invasive ductal carcinoma (IDC) and ductal carcinoma in situ (DCIS) and compare the conventional apparent D (ADC), and mean kurtosis (MK), with the tissue D (D
    Patients and methods: This retrospective study included women who underwent breast MRI with eight b-value diffusion-weighted imaging between February 2019 and March 2022. Spectral diffusion analysis was performed; very-slow, cellular, and perfusion compartments were defined using cut-off Ds of 0.1 × 10
    Results: Histologically confirmed 132 ICD and 62 DCIS (age range 31-87 [53 ± 11] years) were evaluated. The areas under the curve (AUCs) for ADC, MK, D
    Conclusion: Three-compartment model analysis using the diffusion spectrum accurately differentiated IDC from DCIS; however, it was not superior to ADC and D
    Mesh-Begriff(e) Humans ; Female ; Adult ; Middle Aged ; Aged ; Aged, 80 and over ; Breast Neoplasms/diagnostic imaging ; Breast Neoplasms/pathology ; Carcinoma, Intraductal, Noninfiltrating ; Retrospective Studies ; Magnetic Resonance Imaging ; Diffusion Magnetic Resonance Imaging/methods ; Motion
    Sprache Englisch
    Erscheinungsdatum 2023-05-11
    Erscheinungsland Netherlands
    Dokumenttyp Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 604885-7
    ISSN 1873-5894 ; 0730-725X
    ISSN (online) 1873-5894
    ISSN 0730-725X
    DOI 10.1016/j.mri.2023.04.006
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Volltext online

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Zs.A 1817: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  5. Artikel ; Online: Characterizing user demographics in posts related to breast, lung and colon cancer on Japanese twitter (X).

    Kusudo, Maho / Terada, Mitsuo / Kureyama, Nari / Wanifuchi-Endo, Yumi / Fujita, Takashi / Asano, Tomoko / Kato, Akiko / Mori, Makiko / Horisawa, Nanae / Toyama, Tatsuya

    Scientific reports

    2024  Band 14, Heft 1, Seite(n) 6485

    Abstract: Various cancer-related information is spreading on social media. Our study aimed to examine the account types associated with cancer-related tweets (currently known as posts) on Twitter (currently known as X) in Japan, specifically focusing on breast, ... ...

    Abstract Various cancer-related information is spreading on social media. Our study aimed to examine the account types associated with cancer-related tweets (currently known as posts) on Twitter (currently known as X) in Japan, specifically focusing on breast, lung, and colon cancer. Using the Twitter application programming interface, we collected tweets containing keywords of the three cancers type in August-September 2022. The accounts were categorized into seven types: Survivor, Patient's family, Healthcare provider, Public organization, Private organization, News, and Other according to account name and texts. We analyzed the sources of the top 50 most liked and retweeted tweets. Out of 7753 identified tweets, breast cancer represented the majority (62.8%), followed by lung cancer (20.8%) and colon cancer (16.3%). Tweets came from 4976 accounts. Account types varied depending on the cancer type, with breast cancer topics more frequently from Survivor (16.0%) and lung cancer from Patient's family (16.3%). Healthcare provider and Public organization had minimal representation across three cancer types. The trends in the top 50 tweets mirrored the distribution of accounts for each cancer type. Breast cancer-related tweets had the highest frequency. There were few from public organizations. These findings emphasize the need to consider the characteristics of cancer-related information sources when sharing and gathering information on social media.
    Mesh-Begriff(e) Humans ; Female ; Social Media ; Japan/epidemiology ; Colonic Neoplasms/epidemiology ; Breast Neoplasms/epidemiology ; Lung Neoplasms/epidemiology ; Lung ; Demography
    Sprache Englisch
    Erscheinungsdatum 2024-03-18
    Erscheinungsland England
    Dokumenttyp Journal Article
    ZDB-ID 2615211-3
    ISSN 2045-2322 ; 2045-2322
    ISSN (online) 2045-2322
    ISSN 2045-2322
    DOI 10.1038/s41598-024-56679-x
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  6. Artikel ; Online: First-line endocrine therapy for postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer: a systematic review and meta-analysis.

    Shimoi, Tatsunori / Sagara, Yasuaki / Hara, Fumikata / Toyama, Tatsuya / Iwata, Hiroji

    Breast cancer (Tokyo, Japan)

    2020  Band 27, Heft 3, Seite(n) 340–346

    Abstract: Background: In establishing the 2018 Breast Cancer Practice Guidelines of the Japan Breast Cancer Society, we explored the optimal first-line endocrine therapy for advanced postmenopausal hormone receptor-positive breast cancer.: Methods: We ... ...

    Abstract Background: In establishing the 2018 Breast Cancer Practice Guidelines of the Japan Breast Cancer Society, we explored the optimal first-line endocrine therapy for advanced postmenopausal hormone receptor-positive breast cancer.
    Methods: We performed a systematic review of relevant reports from randomized-controlled studies published prior to November 2016 found using medical journal search engines. The main outcomes which we evaluated were progression-free survival (PFS), objective response rate (ORR), disease control rate (CBR), and toxicity.
    Results: Four controlled trials comparing aromatase inhibitors (AI) and cyclin-dependent kinase (CDK)4/6 inhibitor combination therapy to AI monotherapy, and two controlled trials comparing anastrozole to fulvestrant 500 mg were analyzed. AI/CDK4/6 inhibitor combination therapy significantly improved PFS (Risk Ratio: 0.67, 95%CI 0.60-0.73), increased ORR (Risk Difference: 0.11, 95% CI 0.07-0.16), and increased CBR (Risk Difference: 0.11, 95% CI 0.07-0.15), compared with AI monotherapy. Patients who received this combination therapy had a higher grade ≥ 3 adverse event rate more than those who received AI monotherapy (Risk Difference: 43%, 95%CI: 0.39-0.47). Fulvestrant 500 mg alone significantly improved PFS (risk ratio: 0.85, 95%CI 0.72-0.98), but ORR and CBR were similar to those of anastrozole alone.
    Conclusion: In the first-line treatment for advanced postmenopausal hormone receptor-positive breast cancer, a combination therapy of CDK4/6 inhibitors and AI showed significant improvement of PFS, ORR, and CBR but with significant increased toxicities compared with AI alone. Fulvestrant 500 mg monotherapy significantly prolonged PFS compared with AI monotherapy. We must wait for the results of the studies with longer follow-up period.
    Mesh-Begriff(e) Aromatase Inhibitors/therapeutic use ; Biomarkers, Tumor/metabolism ; Breast Neoplasms/drug therapy ; Breast Neoplasms/metabolism ; Breast Neoplasms/pathology ; Female ; Humans ; Postmenopause ; Prognosis ; Receptor, ErbB-2/metabolism ; Receptors, Estrogen/metabolism ; Receptors, Progesterone/metabolism
    Chemische Substanzen Aromatase Inhibitors ; Biomarkers, Tumor ; Receptors, Estrogen ; Receptors, Progesterone ; ERBB2 protein, human (EC 2.7.10.1) ; Receptor, ErbB-2 (EC 2.7.10.1)
    Sprache Englisch
    Erscheinungsdatum 2020-02-11
    Erscheinungsland Japan
    Dokumenttyp Journal Article ; Meta-Analysis ; Systematic Review
    ZDB-ID 2052429-8
    ISSN 1880-4233 ; 1340-6868
    ISSN (online) 1880-4233
    ISSN 1340-6868
    DOI 10.1007/s12282-020-01054-7
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Volltext online

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Zs.A 5536: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  7. Artikel ; Online: Risks and benefits of bevacizumab combined with chemotherapy for advanced or metastatic breast cancer: a meta-analysis of randomized controlled trials.

    Miyashita, Minoru / Hattori, Masaya / Takano, Toshimi / Toyama, Tatsuya / Iwata, Hiroji

    Breast cancer (Tokyo, Japan)

    2020  Band 27, Heft 3, Seite(n) 347–354

    Abstract: Background: The combination of bevacizumab and chemotherapy has greatly improved progression-free survival (PFS) and objective response rate (ORR) in HER2-negative metastatic breast cancer in many pivotal trials. However, risk-benefit balance related to ...

    Abstract Background: The combination of bevacizumab and chemotherapy has greatly improved progression-free survival (PFS) and objective response rate (ORR) in HER2-negative metastatic breast cancer in many pivotal trials. However, risk-benefit balance related to bevacizumab addition could not be confirmed because of a lack of overall survival (OS) improvement. Therefore, we conducted a meta-analysis to evaluate multiple endpoints pertaining to bevacizumab use in metastatic breast cancer (MBC) treatment.
    Methods: We searched PubMed and Cochrane Library databases and included seven studies in our meta-analysis in which bevacizumab combined with chemotherapy was compared with chemotherapy alone in MBC.
    Results: Compared to the chemotherapy-alone group, the combination treatment group had significantly improved PFS [hazard ratio (HR): 0.72, 95% CI 0.67-0.77, P < 0.00001]. Furthermore, bevacizumab addition did not significantly improve OS (HR: 0.95, 95% CI 0.87-1.03, P = 0.22). The ORRs in the combination treatment and chemotherapy-alone groups were 42% and 32%, respectively (HR: 1.47, 95% CI 1.26-1.71, P < 0.00001). Bevacizumab addition significantly increased the incidence of therapy discontinuation due to toxicity and toxicity of grade 3 or higher (HR: 1.43, 95% CI 1.06-1.93, P = 0.02, HR: 1.43; 95% CI 1.25-1.64, P < 0.00001, respectively). A qualitative systematic review of two randomized controlled trials indicated no significant differences in quality of life from baseline between the two groups.
    Conclusions: Compared to chemotherapy alone, bevacizumab combined with chemotherapy significantly improved PFS in the HER2-negative MBC patients. However, the lack of a significant OS difference remained.
    Mesh-Begriff(e) Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Bevacizumab/therapeutic use ; Breast Neoplasms/drug therapy ; Breast Neoplasms/secondary ; Female ; Humans ; Prognosis ; Quality of Life ; Randomized Controlled Trials as Topic ; Risk Assessment/methods
    Chemische Substanzen Bevacizumab (2S9ZZM9Q9V)
    Sprache Englisch
    Erscheinungsdatum 2020-01-23
    Erscheinungsland Japan
    Dokumenttyp Journal Article ; Meta-Analysis
    ZDB-ID 2052429-8
    ISSN 1880-4233 ; 1340-6868
    ISSN (online) 1880-4233
    ISSN 1340-6868
    DOI 10.1007/s12282-020-01052-9
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Volltext online

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Zs.A 5536: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  8. Artikel ; Online: The Japanese Breast Cancer Society Clinical Practice Guidelines for Breast Cancer, 2022 Edition: changes from the 2018 edition and general statements on breast cancer treatment.

    Yamamoto, Yutaka / Yamauchi, Chikako / Toyama, Tatsuya / Nagai, Shigenori / Sakai, Takehiko / Kutomi, Goro / Yoshimura, Michio / Kawai, Masaaki / Ohtani, Shoichiro / Kubota, Kazunori / Nakashima, Kazutaka / Honma, Naoko / Yoshida, Masayuki / Tokunaga, Eriko / Taira, Naruto / Iwata, Hiroji / Saji, Shigehira

    Breast cancer (Tokyo, Japan)

    2024  Band 31, Heft 3, Seite(n) 340–346

    Abstract: The Japanese Breast Cancer Society Clinical Practice Guidelines for Breast Cancer, 2022 Edition was published in June 2022. The guidelines were prepared while conforming as much as possible to the "Minds Manual for Guideline Development 2020 ver. 3.0." ... ...

    Abstract The Japanese Breast Cancer Society Clinical Practice Guidelines for Breast Cancer, 2022 Edition was published in June 2022. The guidelines were prepared while conforming as much as possible to the "Minds Manual for Guideline Development 2020 ver. 3.0." edited by the Minds Manual Development Committee of the Japan Council for Quality Health Care in 2021. In addition, a survey of Japanese Breast Cancer Society members on the 2018 edition of the guidelines was conducted from February 19 to March 4, 2021. Based on the responses from over 600 members, original innovations were made to make the guidelines more user-friendly. The 2018 edition of the guidelines was developed to provide support tools for physicians and patients to utilize shared decision-making. The 2022 guidelines consist of two volumes: (1) an "Epidemiology and Diagnosis" section covering "Screening and Diagnosis", "Radiological diagnosis", and "Pathological diagnosis", and (2) a "Treatment" section covering "Surgical therapy", "Radiation therapy", and "Systemic therapy". We believe that this concise summary of the guidelines will be useful to physicians and researchers in Japan and overseas.
    Mesh-Begriff(e) Humans ; Breast Neoplasms/therapy ; Breast Neoplasms/diagnosis ; Breast Neoplasms/pathology ; Female ; Japan ; Societies, Medical ; Practice Guidelines as Topic ; Medical Oncology/standards ; East Asian People
    Sprache Englisch
    Erscheinungsdatum 2024-04-03
    Erscheinungsland Japan
    Dokumenttyp Journal Article ; Practice Guideline
    ZDB-ID 2052429-8
    ISSN 1880-4233 ; 1340-6868
    ISSN (online) 1880-4233
    ISSN 1340-6868
    DOI 10.1007/s12282-024-01566-6
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Volltext online

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Zs.A 5536: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  9. Artikel ; Online: Correction: The Japanese Breast Cancer Society Clinical Practice Guidelines for Breast Cancer, 2022 Edition: changes from the 2018 edition and general statements on breast cancer treatment.

    Yamamoto, Yutaka / Yamauchi, Chikako / Toyama, Tatsuya / Nagai, Shigenori / Sakai, Takehiko / Kutomi, Goro / Yoshimura, Michio / Kawai, Masaaki / Ohtani, Shoichiro / Kubota, Kazunori / Nakashima, Kazutaka / Honma, Naoko / Yoshida, Masayuki / Tokunaga, Eriko / Taira, Naruto / Iwata, Hiroji / Saji, Shigehira

    Breast cancer (Tokyo, Japan)

    2024  

    Sprache Englisch
    Erscheinungsdatum 2024-05-12
    Erscheinungsland Japan
    Dokumenttyp Published Erratum
    ZDB-ID 2052429-8
    ISSN 1880-4233 ; 1340-6868
    ISSN (online) 1880-4233
    ISSN 1340-6868
    DOI 10.1007/s12282-024-01589-z
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Volltext online

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Zs.A 5536: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  10. Artikel ; Online: Dose-dense adjuvant chemotherapy: a systematic review and meta-analysis of the Japanese Breast Cancer Society Clinical Practice Guideline, 2018 edition.

    Yoshinami, Tetsuhiro / Koizumi, Kei / Nagai, Shigenori E / Toyama, Tatsuya / Iwata, Hiroji

    Breast cancer (Tokyo, Japan)

    2020  Band 27, Heft 3, Seite(n) 334–339

    Abstract: Increasing the dose intensity of cytotoxic therapy by shortening the intervals between cycles may enhance efficacy. Dose-dense chemotherapy, which is adopted as adjuvant chemotherapy of high-risk breast cancer, is addressed in the Japanese Breast Cancer ... ...

    Abstract Increasing the dose intensity of cytotoxic therapy by shortening the intervals between cycles may enhance efficacy. Dose-dense chemotherapy, which is adopted as adjuvant chemotherapy of high-risk breast cancer, is addressed in the Japanese Breast Cancer Society Clinical Practice Guideline for breast cancer, 2018 edition (in Japanese). To evaluate the benefits and safety of dose-dense adjuvant chemotherapy described in the guideline, we performed a systematic review and meta-analysis of data of randomized trials using the same drugs, doses, and numbers of cycles. The PubMed, Cochrane Library, and Ichushi-Web databases were searched for relevant publications reporting randomized trials published until November 2016. Overall survival (OS), disease-free survival (DFS), and toxicity were assessed. Three trials comprising 5190 patients were included. Compared with conventional chemotherapy, dose-dense chemotherapy lengthened OS (RR = 0.76; 95% CI = 0.64-0.90) and DFS (RR = 0.83; 95% CI = 0.75-0.92) and increased the risk of anemia (RR = 4.56; 95% CI = 2.01-10.34). We conclude that dose-dense chemotherapy can be highly recommended as adjuvant chemotherapy for patients with breast cancer with a high risk of recurrence risk and sufficient bone marrow function.
    Mesh-Begriff(e) Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Breast Neoplasms/drug therapy ; Breast Neoplasms/pathology ; Female ; Humans ; Medical Oncology ; Practice Guidelines as Topic/standards ; Prognosis
    Sprache Englisch
    Erscheinungsdatum 2020-01-08
    Erscheinungsland Japan
    Dokumenttyp Journal Article ; Meta-Analysis ; Systematic Review
    ZDB-ID 2052429-8
    ISSN 1880-4233 ; 1340-6868
    ISSN (online) 1880-4233
    ISSN 1340-6868
    DOI 10.1007/s12282-019-01039-1
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Volltext online

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Zs.A 5536: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

Zum Seitenanfang